Bibliography
- European Organization for Rare Disorders. Available from: http://www.eurordis.org [Accessed on 19 August 2013]
- National Organization for Rare Disorders. Available from: http://www.rarediseases.org [Accessed on 19 August 2013]
- US Food and Drug Administration. Orphan Drug Act. Public Law 97-4141983. Available from: http://www.fda.gov/regulatoryinformation/legislation/federalfooddrugandcosmeticactfdcact/significantamendmentstothefdcact/orphandrugact/default.htm [Accessed on 19 August 2013]
- Schieppati A, Henter JI, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet 2008;371(9629):2039-41
- Forrest CB, Bartek RJ, Rubinstein Y, Groft SC. The case for a global rare-diseases registry. Lancet 2011;377(9771):1057-9
- Cole JA, Taylor JS, Hangartner TN, et al. Reducing selection bias in case-control studies from rare disease registries. Orphanet J Rare Dis 2011;6:61
- Gliklich RE, Dreyer NA, editors. Registries for evaluating patient outcomes: a user's guide. (Prepared by Outcome DEcIDE Center [Outcome Sciences, Inc., dba Outcome] under Contract No. HHSA290200500351 TO1.)
- Aymé S, Kole A, Rodwell C. RDTF Report on patient registries the field of rare diseases: overview of the issues surrounding the establishment, governance and financing of academic registries. 2011. Available from: http://www.eucerd.eu/EUCERD/upload/file/RDTFReportRegistriesJuly2011.pdf [Accessed on 19 August 2013]
- Disease Registries in Europe.Orphanet Report Series, Rare Diseases Collection. 2013. Available from: http://www.orpha.net/orphacom/cahiers/docs/GB/Registries.pdf [Accessed on 19 August 2013]
- Webb SM, Santos A, Valassi E. The value of a European registry for pituitary adenomas: the example of Cushing's syndrome registry. Ann Endocrinol (Paris) 2012;73(2):83-9
- Hollak CE, Aerts JM, Ayme S, Manuel J. Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders. Orphanet J Rare Dis 2011;6:16
- Leiva LE, Zelazco M, Oleastro M, et al. Primary immunodeficiency diseases in Latin America: the second report of the LAGID registry. J Clin Immunol 2007;27(1):101-8
- Martins AM, Kerstenezky M, Linares A, et al. Utility of rare disease registries in Latin America. JIMD Rep 2011;1:111-15
- Drelichman G, Linares A, Villalobos J, et al.. Gaucher disease in Latin America. A report from the Gaucher disease international registry and the Latin American group for Gaucher disease. Medicina (B Aires) 2012;72(4):273-82
- Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004;41(4 Suppl 5):4-14
- Sobreira E, Pires RF, Cizmarik M, Grabowski GA. Phenotypic and genotypic heterogeneity in Gaucher disease type 1: a comparison between Brazil and the rest of the world. Mol Genet Metab 2007;90(1):81-6
- Verhulst K, Artiles-Carloni L, Beck M, et al. Source document verification in the mucopolysaccharidosis type I registry. Pharmacoepidemiol Drug Saf 2012;21(7):749-52
- Rubinstein YR, Groft SC, Bartek R, et al. Creating a global rare disease patient registry linked to a rare diseases biorepository database: Rare Disease-HUB (RD-HUB). Contemp Clin Trials 2010;31(5):394-404